HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

637.736

+19.0313.08%

Number of Gainers:22

Number of Losers:8

Number of Flat:4

PE:- -

High:646.735

Open:618.980

Low:611.252

Close:618.706

Volume:128.20M

Turnover:4.02B

Market Cap:394.17B

Float Cap:350.94B

Loading ...

JD HEALTH Launches Over 20 New Medical Devices This Year, 11.11 Sales Surge Over 100% YoY

JW Cayman Therapeutics Signs Amendment to Collaboration Agreement with Regeneron

Great Wall Fund's Healthcare Investment Team Eyes Potential Second Wave in Pharma Sector

Fuling District Market Supervision Bureau Strengthens Implementation of Online Medical Device Sales Quality Management Standards

HBM HOLDINGS-B (02142) Rises Over 4% After Launching First Fully Human HCAb Generation Model to Accelerate Next-Gen Therapies

EVEREST MED (01952) Secures Exclusive Rights to Ophthalmic Bispecific Drug VIS-101, Entering $40 Billion Blue Ocean Market

2025 National Medical Insurance Negotiations Kick Off with Introduction of "Commercial Insurance Innovative Drug List" Mechanism

BRIEF-Everest Medicines Announces Agreement With Visara

HK Stock Connect Shareholding Changes as of October 30

JACOBIO-B (01167) Repurchased 132,000 Shares for Approximately HK$966,000 on October 28

Jacobio Pharmaceuticals Files HKEX Disclosure on Repurchase of 132,000 Shares for HKD 965,984.19

Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies

ASCLETIS-B (01672) Selects Best-in-Class Monthly Subcutaneous Amylin Receptor Agonist ASC36 for Clinical Development

CHINARES PHARMA (03320) Leads Establishment of RMB 500 Million Fund, Focusing on Synthetic Biology and Innovative Drugs

EVEREST MED (01952) Enters Agreement with VISARA for Development and Commercialization of VIS-101 in Greater China and Other Asian Markets

Everest Medicines Secures Exclusive Rights to Develop and Commercialize VIS-101 in Greater China and Asia

Everest Medicines - Agreement With Visara to Develop and Commercialize Vis-101 in Greater China and Other Asian Markets

THOMSON REUTERS

Novabridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for Vis-101 in Greater China and Certain Other Asian Countries

THOMSON REUTERS

CanSino Biologics Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Simply Wall St.

Zhong Huijuan and Daughter Top China's Richest Women List with $141 Billion Fortune

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":637.73645,"timestamp":1762157288176,"preClose":618.7055,"halted":0,"volume":128198934,"delay":0,"changeRate":0.030759,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":19.030945,"latestTime":"11-03 16:00:00","open":618.97986,"high":646.73535,"low":611.2518,"amount":4019731835,"amplitude":0.057351,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762219800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1762133400000,1762142400000],[1762146000000,1762156800000]],"pbRate":5.343409,"peRate":-44.036334,"turnoverRate":0.004676,"increases":23,"decrements":8,"flats":2,"marketCap":394165077952,"floatMarketCap":350938497872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":646.73535,"amplitude":0.057351,"preClose":618.7055,"low":611.2518,"pbRate":"5.343409","latestPrice":637.73645,"volume":128198934,"delay":0,"open":618.97986,"prevYearClose":331.1933,"prevWeekClose":618.706,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":617.318,"twentyDayClose":766.012,"sixtyDayClose":789.562,"secType":"PLATE","market":"HK","turnoverRate":0.004676,"peRate":-44.036334,"marketCap":394165077952,"floatMarketCap":350938497872,"timestamp":1762157288176,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":22,"down":8,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1133999426","title":"JD HEALTH Launches Over 20 New Medical Devices This Year, 11.11 Sales Surge Over 100% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1133999426","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133999426?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:41","pubTimestamp":1761817303,"startTime":"0","endTime":"0","summary":"On October 30, JD HEALTH announced during a media event with Yuwell Medical that it has introduced more than 20 new medical devices this year as a global online launch platform. These include...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1142","BK1247","BK1515","09996","BK1574","LU0456827905.SGD","06618","BK1222","BK1589","BK1100","BK1571","LU0051755006.USD","SGXZ62798434.SGD","159883","BK1615","BK1591","09997","BK1583","86618","SGXZ86797644.SGD"],"gpt_icon":1},{"id":"2579118214","title":"JW Cayman Therapeutics Signs Amendment to Collaboration Agreement with Regeneron","url":"https://stock-news.laohu8.com/highlight/detail?id=2579118214","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579118214?lang=en_us&edition=fundamental","pubTime":"2025-10-30 17:34","pubTimestamp":1761816870,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics Co. Ltd. announced a major transaction involving Amendment No. 1 to its Collaboration Agreement. The amendment, dated October 30, 2025, involves JW Cayman, JW Shanghai, and Regeneron. Under the terms of the amendment, Regeneron has agreed to fund certain development activities related to the MAGE-A4 Product, including making an upfront payment to the company. The collaboration agreement was originally established between JW Cayman and 2seventy bio on October 27, 2022, and was assigned to Regeneron effective April 1, 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL39sr0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","BK4585","LU2023250504.SGD","LU2362541513.USD","LU2106854487.HKD","LU2362541273.HKD","LU0882574055.USD","BK4139","BK1583","BK4588","LU0058720904.USD","LU0320765992.SGD","BK1161","LU0823434740.USD","LU0109394709.USD","LU1974910355.USD","LU2468319806.SGD","LU2362540622.SGD","LU0823434583.USD","LU2237438978.USD","BK1574","LU1917777945.USD","LU0889565916.HKD","LU0289739699.SGD","02126","LU0053666078.USD","REGN","LU0114720955.EUR","LU0823416689.USD"],"gpt_icon":0},{"id":"1156751703","title":"Great Wall Fund's Healthcare Investment Team Eyes Potential Second Wave in Pharma Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1156751703","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156751703?lang=en_us&edition=fundamental","pubTime":"2025-10-30 16:51","pubTimestamp":1761814283,"startTime":"0","endTime":"0","summary":"Currently, China's economic fundamentals remain stable, with policies entering a critical window period. Meanwhile, the external environment is complex, as the trajectory of U.S.-China trade...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1515","BK1574","159938","BK1161"],"gpt_icon":0},{"id":"1199736295","title":"Fuling District Market Supervision Bureau Strengthens Implementation of Online Medical Device Sales Quality Management Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1199736295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199736295?lang=en_us&edition=fundamental","pubTime":"2025-10-30 13:31","pubTimestamp":1761802286,"startTime":"0","endTime":"0","summary":"In recent days, the Fuling District Market Supervision Bureau in Chongqing has taken multiple measures to actively promote and implement the \"Online Medical Device Sales Quality Management Standards\"...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","09997","09996","159883","BK1222","BK1100","BK1574"],"gpt_icon":0},{"id":"1145278677","title":"HBM HOLDINGS-B (02142) Rises Over 4% After Launching First Fully Human HCAb Generation Model to Accelerate Next-Gen Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1145278677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145278677?lang=en_us&edition=fundamental","pubTime":"2025-10-30 11:08","pubTimestamp":1761793695,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) surged more than 4%, reaching HK$13.49 by the time of writing, with a trading volume of HK$52.54 million. The company announced the launch of its Hu-mAtrIx™ AI-powered fully...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","02142"],"gpt_icon":0},{"id":"1167592945","title":"EVEREST MED (01952) Secures Exclusive Rights to Ophthalmic Bispecific Drug VIS-101, Entering $40 Billion Blue Ocean Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1167592945","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167592945?lang=en_us&edition=fundamental","pubTime":"2025-10-30 10:42","pubTimestamp":1761792176,"startTime":"0","endTime":"0","summary":"On October 30, Hong Kong-listed biopharmaceutical company EVEREST MED (01952) announced an agreement with Visara to obtain exclusive rights for the clinical development, production, and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","BK4585","01952","BK1583","VIS","BK1574"],"gpt_icon":0},{"id":"1156670626","title":"2025 National Medical Insurance Negotiations Kick Off with Introduction of \"Commercial Insurance Innovative Drug List\" Mechanism","url":"https://stock-news.laohu8.com/highlight/detail?id=1156670626","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156670626?lang=en_us&edition=fundamental","pubTime":"2025-10-30 10:20","pubTimestamp":1761790838,"startTime":"0","endTime":"0","summary":"The 2025 National Medical Insurance Negotiations commenced in Beijing on October 30. This year’s negotiations mark the first official introduction of the \"Commercial Insurance Innovative Drug List\"...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","159992","06978"],"gpt_icon":0},{"id":"2579152531","title":"BRIEF-Everest Medicines Announces Agreement With Visara","url":"https://stock-news.laohu8.com/highlight/detail?id=2579152531","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579152531?lang=en_us&edition=fundamental","pubTime":"2025-10-30 09:25","pubTimestamp":1761787509,"startTime":"0","endTime":"0","summary":"BRIEF-Everest Medicines Announces Agreement With VisaraOct 30  - Everest Medicines Ltd 1952.HK:AGREEMENT WITH VISARA TO DEVELOP AND COMMERCIALIZE VIS-101 IN GREATER CHINA AND OTHER ASIAN MARKETSTO PAY US$7 MILLION UPFRONTFurther company coverage: 1952.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WA2K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"1112926226","title":"HK Stock Connect Shareholding Changes as of October 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1112926226","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112926226?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:38","pubTimestamp":1761784715,"startTime":"0","endTime":"0","summary":"As of October 28, 2025, data shows that **SANHUA (02050)**, **CHIFENG GOLD (06693)**, and **QUNABOX GROUP (00917)** recorded the largest increases in Stock Connect shareholding ratios, rising by...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","00168","02465","BK1515","BK1568","02162","BK1183","03677","BK1594","BK1505","LU0572939691.SGD","01528","BK1604","BK1208","IE00B031HY20.USD","00189","BK1137","BK1574","LU1226287529.USD","BK1510","BK1584","SG9999006597.SGD","BK1535","BK1154","BK1236","LU0880133367.SGD","02402","BK1592","03993","BK1591","LU1152091168.USD","LU1951186391.HKD","LU0264606111.USD","BK1175","HK0000500386.USD","BK1225","BK1522","LU1152091754.HKD","BK1521","LU0140636845.USD","BK1104","02169","LU1226287875.USD","BK1241","BK1173","LU1831875114.USD","02208","BK1138","LU0326950275.SGD","01033","LU2543165471.USD","03678","BK1109","LU0405327148.USD","BK1207","BK1526","03069","LU1813983027.USD","BK1562","01336","BK1576","01057","BK1513","LU0181495838.USD","IE00BZ08YR35.GBP","BK1613","BK1116","06682","LU0588546209.SGD","BK1110","BK1191","BK1124","BK1129","BK1171","BK1205","06680","IE00B5MMRT66.SGD","LU0244354667.USD","LU1960683339.HKD","00588","IE00B543WZ88.USD","BK1148","BK1229","HK0000252160.HKD","01093","BK1511","02255","LU1188198961.HKD","09606","00358","BK1550","06936","BK1198","BK1523","09696","BK1564","03347","BK1516","LU1328277881.USD","03369","HK0000252152.HKD","LU1481107354.HKD","BK1190","01119","02050","IE0008368742.USD","IE00BZ08YT58.USD","BK1501","BK1610","SG9999004220.SGD","02945","02367","06616","LU1807302812.USD","LU1226288253.USD","BK1552","02828","BK1506","BK1544","BK1583","LU2039709279.SGD","00917","01341","01729","LU1969619763.USD","09660","IE00BGV7N243.SGD","01053","LU0315179316.USD","LU0149721374.USD","BK1558","LU0067412154.USD","02533","02068","01709","LU0327786744.USD","02600","01072","LU0572940350.SGD","09880","00564","LU0072913022.USD","IE0008369823.USD","LU0314109678.HKD","BK1546","LU1008478684.HKD","BK1240","BK1180","BK1578","LU0572944931.SGD","LU1993786604.SGD","SG9999004311.SGD","09878","BK1531","BK1202","02648","00895","BK1147","01787","BK1206","LU0164880469.USD","LU0463099449.HKD","BK1614","IE00BZ08YS42.EUR","02837","09995","BK1140","BK1149","LU2328871848.SGD","02582","BK1163","BK1221","LU0405327494.USD","BK1237","06869","01635","BK1258","LU2213484517.USD","LU0307460666.USD","MCHmain","LU1226287792.SGD","BK1537","01385","LU0828237940.HKD","00412","06693","LU2488822045.USD","BK1144","BK1587","LU0501845795.SGD","LU1226288170.HKD","BK1184","01065","SG9999014674.SGD","BK1151","BK1141"],"gpt_icon":1},{"id":"1110115052","title":"JACOBIO-B (01167) Repurchased 132,000 Shares for Approximately HK$966,000 on October 28","url":"https://stock-news.laohu8.com/highlight/detail?id=1110115052","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110115052?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:26","pubTimestamp":1761783968,"startTime":"0","endTime":"0","summary":"JACOBIO-B (01167) announced that on October 28, 2025, the company repurchased 132,000 shares at a total cost of approximately HK$966,000.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","BK1574","BK1161"],"gpt_icon":0},{"id":"2579591831","title":"Jacobio Pharmaceuticals Files HKEX Disclosure on Repurchase of 132,000 Shares for HKD 965,984.19","url":"https://stock-news.laohu8.com/highlight/detail?id=2579591831","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579591831?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:25","pubTimestamp":1761783904,"startTime":"0","endTime":"0","summary":"Jacobio Pharmaceuticals Group Co. Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, announcing the repurchase of 132,000 shares at a volume-weighted average price of HKD 7.318062 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobio Pharmaceuticals Group Co. Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL9N68LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01167","BK1574","BK1161"],"gpt_icon":0},{"id":"2579315619","title":"Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2579315619","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579315619?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:10","pubTimestamp":1761783024,"startTime":"0","endTime":"0","summary":"Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as a clinical development candidate for the treatment of obesity. In preclinical studies, ASC36 showed an average observed half-life of approximately 15 days in non-human primates, which is three times longer than petrelintide, supporting its potential for once-monthly dosing in humans. Additionally, ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a diet-induced obese rat study. The company expects to submit an Investigational New Drug Application  for ASC36 to the U.S. FDA in the second quarter of 2026. These results and further plans for monotherapy and combination therapies with ASC36 were announced but have not yet been presented at a scientific conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLch5r9m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","01672"],"gpt_icon":0},{"id":"1135533889","title":"ASCLETIS-B (01672) Selects Best-in-Class Monthly Subcutaneous Amylin Receptor Agonist ASC36 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1135533889","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135533889?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:10","pubTimestamp":1761783013,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced the selection of ASC36, a potential best-in-class monthly subcutaneous amylin receptor agonist, as its clinical development candidate. The company plans to submit an...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1515","BK1574","BK1161","BK1191","01672"],"gpt_icon":0},{"id":"1102883267","title":"CHINARES PHARMA (03320) Leads Establishment of RMB 500 Million Fund, Focusing on Synthetic Biology and Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1102883267","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102883267?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:06","pubTimestamp":1761782773,"startTime":"0","endTime":"0","summary":"CHINARES PHARMA (03320) announced that on October 29, 2025, CHINARES PHARMA (Shantou) (as the general partner), CHINARES DOUBLE-CRANE (as the limited partner), and CHINARES PHARMA Investment (as the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1570","BK1574","BK1161","03320","159992","BK1191","06978"],"gpt_icon":0},{"id":"1117450614","title":"EVEREST MED (01952) Enters Agreement with VISARA for Development and Commercialization of VIS-101 in Greater China and Other Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=1117450614","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117450614?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:12","pubTimestamp":1761779537,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced that on October 28, 2025, the company entered into an agreement with Visara, Inc. (VISARA), a subsidiary of NewBridge Pharmaceuticals (formerly known as I-Mab, listed on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","VIS","BK1574","BK1583","01952","BK4585","BK4588"],"gpt_icon":0},{"id":"2579814153","title":"Everest Medicines Secures Exclusive Rights to Develop and Commercialize VIS-101 in Greater China and Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2579814153","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579814153?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:03","pubTimestamp":1761778997,"startTime":"0","endTime":"0","summary":"Everest Medicines Limited announced that it has entered into an agreement with Visara, Inc., a subsidiary of NovaBridge Biosciences, to acquire exclusive rights to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain other Asian markets. VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, intended for the treatment of wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The agreement allows Everest Medicines to expand into the ophthalmology therapeutic area. The transaction does not constitute a disclosable transaction under the Hong Kong Stock Exchange listing rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Lt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL54wRgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2579153894","title":"Everest Medicines - Agreement With Visara to Develop and Commercialize Vis-101 in Greater China and Other Asian Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2579153894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579153894?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:02","pubTimestamp":1761778970,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nFWN3WA2K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2579301641","title":"Novabridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for Vis-101 in Greater China and Certain Other Asian Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=2579301641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579301641?lang=en_us&edition=fundamental","pubTime":"2025-10-30 06:27","pubTimestamp":1761776866,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nFWN3WA2EV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1574","01952"],"gpt_icon":0},{"id":"2579845166","title":"CanSino Biologics Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2579845166","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579845166?lang=en_us&edition=fundamental","pubTime":"2025-10-30 06:23","pubTimestamp":1761776602,"startTime":"0","endTime":"0","summary":"Investors in CanSino Biologics Inc. ( HKG:6185 ) had a good week, as its shares rose 4.1% to close at HK$44.92...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-inc-beat-analyst-profit-forecasts-and-anal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6185/cansino-biologics-shares/news/cansino-biologics-inc-beat-analyst-profit-forecasts-and-anal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","BK1191","06185","BK1515"],"gpt_icon":0},{"id":"1163899812","title":"Zhong Huijuan and Daughter Top China's Richest Women List with $141 Billion Fortune","url":"https://stock-news.laohu8.com/highlight/detail?id=1163899812","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163899812?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:20","pubTimestamp":1761736857,"startTime":"0","endTime":"0","summary":"China's pharmaceutical power couple has reached new heights of wealth. On October 28, 2025, the Hurun Research Institute released its annual rich list, revealing that Zhong Huijuan, Chairwoman and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","09939","BK1161","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":5,"totalSize":234,"code":"91000000","status":"200"}]}}